---
layout: post
title: "Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV"
date: 2026-02-05 19:00:56 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-21253
original_published: 2022-09-30 00:00:00 +0000
significance: 8.00
---

# Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV

**Published:** February 05, 2026 19:00 UTC
**Source:** Federal Register
**Original Published:** September 30, 2022 00:00 UTC
**Document Number:** 2022-21253

## Summary

This final rule adopts without change an interim final rule with request for comments published in the Federal Register on April 7, 2022, placing daridorexant ([(S)-2-(5-chloro-4-methyl-1H- benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl](5-methoxy-2-(2H-1,2,3- triazol-2-yl)phenyl)methanone), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of such isomers is possible, in schedule IV of the Controlled Substances Act (CSA). With the issuance of this final rule, the Drug Enforcement Administration maintains daridorexant in schedule IV of the CSA.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/09/30/2022-21253/schedules-of-controlled-substances-placement-of-daridorexant-in-schedule-iv)
- API: https://www.federalregister.gov/api/v1/documents/2022-21253

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
